Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion type Assertion NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_head.
- NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion description "[In vitro and in vivo functional studies, including the use of antisense 'antagomir' oligonucleotides, confirmed the key role of miR-221/-222 in regulating the progression of human melanoma; this suggests that targeted therapies suppressing miR-221/-222 may prove beneficial in advanced melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_provenance.
- NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion evidence source_evidence_literature NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_provenance.
- NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion SIO_000772 18417445 NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_provenance.
- NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion wasDerivedFrom befree-20150227 NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_provenance.
- NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_assertion wasGeneratedBy ECO_0000203 NP998726.RA3B3PPeTCCdED4IaIDUGUchMmYS82zV-flfeszQ_n9qs130_provenance.